Abstract
Multiple myeloma (MM) is characterized, in about 80% of cases, by the production of monoclonal intact immunoglobulin and more than 95% of them have elevated concentrations of involved (i.e. of the same class of intact immunoglobulin) free light chain (FLC). The introduction of novel therapeutic strategies has changed the natural history of the disease, leading to new manifestations of relapse. Light chain escape (LCE) is a pattern of relapse in which the FLC increase is not accompanied by a concomitant raise of the original monoclonal component (MC). Here we present a case of a 55-year-old man with an IgG kappa MM stage III diagnosed in September 2007. At presentation an IgG kappa MC and urine Bence Jones protein (BJP) kappa were present. Bone marrow biopsy (BMB) showed the presence of 80% monotypic kappa plasma cells (PCs). The patient received bortezomib, thalidomide, dexamethasone before undergoing a double autologous stem cell transplantation (ASCT) in October 2008 and April 2009. In May 2011 he relapsed showing the same pattern of presentation and treatment with lenalidomide and dexamethasone was started. ln May 2013 serum and urine immunofixation and FLC became negative. In September 2014, an increase of kappa FLC was observed, while serum and urine immunofixations remained negative until January 2015, when urine immunofixation became positive. Eventually, in February 2015, serum immunofixation revealed the presence of a free kappa MC. After a new BMB showing 80% of monotypic kappa PCs, a LCE relapse was diagnosed and the patient started the treatment with bendamustine, bortezomib and dexamethasone. In the present case, the increase of kappa FLC has indicated relapse 4 and 5 months earlier than urine and serum IFE, respectively. Our observation confirms that it is advisable to routinely perform FLC or BJP during follow up of MM patients undergoing ASCT and/or treatment with biological drugs to ensure that LCE is not missed.
References
1. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012;120:1077–86.10.1182/blood-2012-03-412981Search in Google Scholar PubMed
2. Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 2014;123:3414–9.10.1182/blood-2013-12-542662Search in Google Scholar PubMed
3. Durie BG, Harousseau J-L, Bladé J, Barlogie B, Anderson K, Gertz M, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.10.1038/sj.leu.2404284Search in Google Scholar PubMed
4. Hobbs JR. Growth rates and responses to treatment in human myelomatosis. Brit J Haematol 1969;16:607–17.10.1111/j.1365-2141.1969.tb00441.xSearch in Google Scholar PubMed
5. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chain. Haematologica 2007:92:143–4.10.3324/haematol.10297Search in Google Scholar PubMed
6. Kühnemund A, Liebisch P, Bauchmüller K, zurHausen A, Veelken H, Engelhardt M. ‘Light-chain escape-multiple myeloma’ – an escape phenomenon from plateau phase: report of the largest patient series using LC monitoring. J Cancer Res ClinOncol 2009;135:477–84.10.1007/s00432-008-0470-7Search in Google Scholar PubMed
7. Qu X, Zhang L, Fu W, Zhang H, Xiang X, Qiu L, et al. An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers. Leuk Lymphoma 2010;51:1844–9.10.3109/10428194.2010.506933Search in Google Scholar PubMed
8. Zamarin D, Giralt S, Landau H, Lendvai N, Lesokhin A, Chung D, et al. Patterns of relapse and progression in multiple myeloma patients after autologous stem cell transplantation: implications for patients monitoring after transplantation. Bone Marrow Transplant 2013;48:419–24.10.1182/blood.V118.21.825.825Search in Google Scholar
9. Ahn JS, Jung SH, Yang DH, Bae SY, Kim YK, Kim HJ, et al. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2014;14:389–94.10.1016/j.clml.2014.02.004Search in Google Scholar PubMed
10. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24.10.1038/leu.2008.307Search in Google Scholar PubMed
©2016 by De Gruyter
